UPDATE: BofA/Merrill Lynch Upgrades Esperion Therapeutics (ESPR) to Neutral
Tweet Send to a Friend
(Updated - May 6, 2019 1:36 PM EDT)
(updated to add analyst comments)BofA/Merrill Lynch analyst Ying Huang upgraded Esperion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
(updated to add analyst comments)BofA/Merrill Lynch analyst Ying Huang upgraded Esperion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
